Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
- News
- Research
- Sales
- Regulatory
- Healthcare
- Marketing
Oxford BioTherapeutics announces clinical milestones from its collaboration with Boehringer Ingelheim
The collaboration began in 2013 and was later expanded in 2020 and 2023
Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Roche’s Enspryng given FDA Priority Review as thyroid eye disease treatment
This is the first and only at-home subcutaneous treatment option for this disease
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
PMEA welcome Simon Bates as new Chair of the judging panel
Roche and Alnylam share their experiences entering the PMEAs
Latest content
Candel Therapeutics appoints Mark Sims as Chief Commercial Officer
Sims previously held senior level roles at AstraZeneca, Novartis and Merck
Read More
MRM Health appoints Hans-Jürgen Wörle as Independent Director
Wörle previously held senior roles at Nestlé Health Science and Boehringer Ingelheim
Read More
MRM Health appoints Michel Detheux as Chairman of the Board
Detheux was previously founding CEO of iTeos Therapeutics
Read More
Lundbeck appoints Tarek Samad as EVP, Head of Research & Development
Samad previously held senior research leadership positions at Immunitas Therapeutics, Sanofi and Pfizer
Read More
Intelligence
Steering generative AI into the pharma fast lane
Industry needs to press the accelerator to adopt AI across functions to
supercharge launch excellence
Bridging the gap between European brain innovation and real-world policy
Aligning policy and public funding strategies to support brain health across Europe
Read More
Obesity care in the UK – why it can’t improve until it is recognised as a disease
The WHO classified obesity as a chronic disease over twenty years ago – but UK policy has yet to follow
Read More
The next frontier in clinical trials: navigating multi-disease research with GLP-1s
As GLP-1s redefine the treatment landscape for obesity, they are also promising candidates to influence a wide range of disease pathways
Read More
Headline trade and market deals are opening doors to greater patient access
Regulatory changes and tariffs have created a positive climate for investment, innovation and, critically, patient access to therapies
Read More
Men’s health: the gap between awareness and action is where men’s lives are lost
Until the gap between what healthcare systems can offer and how men actually engage with them is closed, outcomes will continue to deteriorate
Read More
Blogs
Latest
Supporting our team with an award-winning mental health strategy
June 26, 2026 | Mednet|Making Health Whole, Mental Health Awareness, Mental Health Strategy
Mental health has been at the centre of our business since our inception. But that work doesn’t just extend to our client projects. Find out …
Genesis Research Group launches free access to EVID AI, its full-spectrum evidence synthesis platform, through 2026
June 24, 2026 | Genesis Research Group|AI, HEOR, Market Access, RWE, evidence, evidence synthesis, genesis, literature reviews, slr
Genesis Research Group today announced that its EVID AI evidence synthesis platform will be available free of charge through 2026 for approved life sciences organizations …
Medscape Education to Showcase the Impact of Neurology CME at EAN 2026
June 23, 2026 | Medscape Education|
Medscape Education, the leading global provider of continuing medical education (CME), has announced its agenda for the upcoming 12th Congress of the European Academy of …
Designing Pharma Stands That People Actually Want to Step Onto
June 18, 2026 | Apex Events and Exhibitions|Exhibition Stand Design, Exhibition Stands, events and exhibitions, pharma exhibitions
Exhibition halls are busy environments where delegates move quickly, often with limited time. For pharmaceutical companies, this presents a challenge: how do you create a …
J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment
June 17, 2026 | Uniphar|
Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial TOKYO, Japan and DUBLIN, Ireland — …
It’s time to stop calling adverse events ‘manageable’
June 29, 2026 | Cuttsy + Cuttsy|Adverse effects, Manageable toxicity, clinical trial, patient engagement, patient experience
A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication reflected patients’ lived experience more clearly.
The value: why localisation pays off across global trials
June 26, 2026 | Cuttsy + Cuttsy|Localisation, clinical trials, translation
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
Live Webinar | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
June 18, 2026 | Inizio|
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
The solution: Good localisation doesn’t feel translated
June 18, 2026 | Cuttsy + Cuttsy|Engagement, Inclusion, Localisation, Trusted information, clinical trials, translation
Learn what good localisation looks like in clinical trials and why participant-facing materials should feel naturally relevant, culturally appropriate and easy to understand across every …
Good Patient Partnership Guide 2026: Patient Journey Mapping with the Patient Community
June 18, 2026 | Precision AQ|
Patient insight gathering and journey mapping can inform and enhance decision making and initiatives across life sciences. The Good Patient Partnership Guide 2026 brings together …